Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
Jason,
This is true:
"INK Research’s Venture indicator is at 715 per cent today, just 20 percentage points below its record peak of 735 per cent set on Oct. 27, 2008. That means there are more than seven stocks listed on the exchange with insider buying for every one seeing selling. It also marks a steep increase since early March, when the indicator was near 400 per cent."
2 Biotechs With Recent Intensive Insider Selling [View article]
arthurs1,
You are right. From ISIS:
ISIS-TTRRx is an antisense drug we designed to treat transthyretin amyloidosis, or TTR amyloidosis, a severe and rare genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues. In patients with TTR amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract. The presence of TTR fibrils interferes with the normal functions of these tissues, and as the TTR protein fibrils enlarge more tissue damage occurs and the disease worsens. http://bit.ly/13N6Ydk
From ALNY:
We are developing ALN-TTR, a systemically delivered RNAi therapeutic that targets the transthyretin (TTR) gene, to treat TTR-mediated amyloidosis (ATTR).
ATTR is caused by mutations in the TTR gene, which is expressed predominantly in the liver. Mutations in TTR cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory neuropathy, autonomic neuropathy, and/or cardiomyopathy.
2 Healthcare Companies With Recent Intensive Insider Selling [View article]
rickevan,
"Pfizer updated certain components of its 2013 financial guidance to reflect the impact of recent changes in foreign exchange rates and the initial public offering (IPO) of a 19.8% ownership interest in Zoetis(1)completed on February 6, 2013, among other factors. Pfizer continues to consolidate Zoetis(1), as Pfizer retains an 80.2% ownership interest. The earnings attributable to the divested interest in Zoetis(1) (Net income attributable to noncontrolling interests) are excluded from Adjusted(2) and Reported(3) Net Income, effective February 7, 2013." http://on.pfizer.com/1...
Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
Good work. Rainy River had NPV of $931 million at $1,400 gold price:
http://bit.ly/15iPMdB
If we get the deal today for Sabina, I believe the premium would be similar to Rainy River.
Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
Made the fix.
2 Basic Materials Stocks With Recent Intensive Insider Selling [View article]
This is possible. That is why I wrote:
"Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart."
Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
Just got insider buy transaction in Continental Gold on June 17:
http://bit.ly/128tCIX
2 Biotechs With Recent Intensive Insider Selling [View article]
The short interest in ILMN has been very steady for months:
http://bit.ly/11kSx0q
2 REITs With Recent Intensive Insider Buying [View article]
Both of these companies did see intensive insider buying:
Intensive insider buying can be defined by the following three criteria:
1. The stock is purchased by three or more insiders within one month.
2. The stock is sold by no insiders in the month of intensive purchasing.
3. At least two purchasers increase their holdings by more than 10%.
Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
Sabina Gold & Silver Trading Below Sum Of The Parts [View article]
This is true:
"INK Research’s Venture indicator is at 715 per cent today, just 20 percentage points below its record peak of 735 per cent set on Oct. 27, 2008. That means there are more than seven stocks listed on the exchange with insider buying for every one seeing selling. It also marks a steep increase since early March, when the indicator was near 400 per cent."
http://bit.ly/193tr8I
1 Tech, 1 Utilities And 1 Consumer Goods Company With Recent Intensive Insider Buying [View article]
Which company are you referring to?
2 Biotechs With Recent Intensive Insider Selling [View article]
You are right. From ISIS:
ISIS-TTRRx is an antisense drug we designed to treat transthyretin amyloidosis, or TTR amyloidosis, a severe and rare genetic disease in which the patient inherits a mutant gene that produces a misfolded form of TTR, which progressively accumulates in tissues. In patients with TTR amyloidosis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract. The presence of TTR fibrils interferes with the normal functions of these tissues, and as the TTR protein fibrils enlarge more tissue damage occurs and the disease worsens.
http://bit.ly/13N6Ydk
From ALNY:
We are developing ALN-TTR, a systemically delivered RNAi therapeutic that targets the transthyretin (TTR) gene, to treat TTR-mediated amyloidosis (ATTR).
ATTR is caused by mutations in the TTR gene, which is expressed predominantly in the liver. Mutations in TTR cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory neuropathy, autonomic neuropathy, and/or cardiomyopathy.
http://bit.ly/13N6W52
2 Biotechs With Recent Intensive Insider Selling [View article]
I agree with you. Just looking for a trade with ILMN with a $61 price target.
2 Biotechs With Recent Intensive Insider Selling [View article]
ISIS could make it to the $31 price target this year:
http://bit.ly/RwwAoS
I don't have currently any position in ISIS because it would be against my trading rules.
2 Healthcare Companies With Recent Intensive Insider Selling [View article]
"Pfizer updated certain components of its 2013 financial guidance to reflect the impact of recent changes in foreign exchange rates and the initial public offering (IPO) of a 19.8% ownership interest in Zoetis(1)completed on February 6, 2013, among other factors. Pfizer continues to consolidate Zoetis(1), as Pfizer retains an 80.2% ownership interest. The earnings attributable to the divested interest in Zoetis(1) (Net income attributable to noncontrolling interests) are excluded from Adjusted(2) and Reported(3) Net Income, effective February 7, 2013."
http://on.pfizer.com/1...
3 REITs With Recent Intensive Insider Buying [View article]
Here is my latest on SBY:
http://seekingalpha.co...
1 Biotech And 1 Consumer Goods Company With Recent Intensive Insider Buying [View article]
The insiders of NVAX did time their buys well in May 2012:
http://seekingalpha.co...
Let's see how the timing works this time.